Anetumab Ravtansine and MK-3475: Treating Pleural Mesothelioma Patients

Randomized Phase 1/Phase 2 Study

This clinical trial is currently recruiting for the Mayo Clinic located in Rochester, Minnesota. The study plans to enroll 134 people.

The clinical study will be divided into phase 1 and phase 2. During the trial, patients will be randomly placed into two groups.

• 1

  Group 1 (Phase 1):

• 2

  Group 2 (Phase 2):

Enrollees in the study will have their treatment repeat every 21 days for potentially up to 2 years. Individuals in either group will continue to receive treatment as long as they do not show signs of toxicity or their disease doesn’t progress.

If a participant in Group 1 is showing signs of disease progression, upon approval, they may be given an opportunity to receive the same treatment as individuals in Group 2. They will be able to continue getting treatment with anetumab ravtansine and pembrolizumab until they show signs of disease progression or unsafe levels of toxicity.

After completing the study, participants will receive follow-ups for 12 months.

Meet the Lead Investigator: Dr. Mansfield

Head of this clinical trial is Dr. Aaron S. Mansfield. Dr. Mansfield is a researcher at the Mayo Clinic Cancer Center in Rochester, MN. He is actively involved in clinical trials that are focused on lung cancer and mesothelioma.

Dr. Mansfield has an interest in studying how tumors avoid destruction by the immune system. He hopes that his research and involvement in early-phase clinical trials will one day provide new life-saving treatments for mesothelioma patients.

Pleural Mesothelioma Patient: Is This Trial for You?

To participate in this clinical trial, a patient must have a confirmed diagnosis of malignant pleural mesothelioma. For phase 2 of the study, a patient’s tumors must showcase at least 30% of mesothelin expression.

All of the participants in the trial must have experienced chemotherapy treatment. It is acceptable for prior chemotherapy treatment to have included the drug bevacizumab. However, patients must not have been treated with a PD-1, PD-L1, or PD-L2 inhibitor.

Some other factors that may exclude a candidate are:

• Receiving monoclonal antibody therapy within 4 weeks of starting the study.
• Currently trying other investigational agents.
• Patient hasn’t fully recovered from surgery or any other anti-cancer therapy.
• Currently taking medications or substances that inhibit or induce CYP3A4 within 2 weeks of participation.

Before a patient believes that this is the right clinical trial for them, they must agree to all terms of the study. For example, this clinical trial may prohibit a patient from receiving certain types of treatment outside of the study.

For instance, patients may not be able to participate in:

• Chemotherapy
• Biological therapy
• Immunotherapy
• Radiation therapy
• Any other form of investigation agents

For more information about this clinical trial, please contact Jenna Campagna. You can reach her at 888-385-2024 extension 102 or by emailing jenna@mesotheliomaguide.com.